KPRX · Kiora Pharmaceuticals Inc
$2.57
+0.00 (+0.00%)
At close · Jul 29
Going-concern doubt
— flagged May 8, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our Condensed Consolidated Financial Statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities or any other adjustments that might be necessary should we be unable to continue as a going concern.”View the 10-Q filed May 8, 2026
Market Cap
$11.39M
Shares
4.43M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.57
Open$2.51
Day$2.51–2.59
52W$1.77–3.01
Avg vol 30d24K
Short int8K · 0.2% float · 1.0d
Short vol21%
DataJan 2020–Jul 2026
Filing10-Q · May 8
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 8, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+11%
above
Price vs 50-day avg
−1%
below
RSI (14)
52
neutral
MACD trend
Positive
52-week position
65%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−2%
trailing
6-month return
+17%
trailing
YTD return
+30%
this year
Relative strength
+11%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow
Flat
2 of 18 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.19% of float · ▲ +16.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
18 holders — mid 2-yr range
Squeeze score
34
low risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
−403%
Y/Y
Free cash flow
$-10.1M
Balance sheet
$8.4M
net cash
Quant / Vol
risk profile
Volatility
62%
annualized · 1-yr
Max drawdown
−39%
past year
ATR
4.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+11%
Bullish
Price vs 50-day avg
−1%
Neutral
RSI (14)
52
Neutral
MACD trend
Positive
Bullish
52-week position
65%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $3 › 200d $2 — 50d above 200d
Institutional flow
Flat
2 of 18 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.19% of float · ▲ +16.3% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
18 holders — mid 2-yr range
Price context
position in its 52-week range
52-wk low $2
Now $3 · 65%
52-wk high $3
vs 200-day avg +11%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KPRX
this stock
Kiora Pharmaceuticals Inc
|
$11.39M | +30.5% | -100.0% | — | 0.2% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +7.7% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +6.6% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +4.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KPRX | +1.6% | -2.3% | +17.4% | -2.3% | +30.5% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | +4.0% | +0.0% | +11.0% | +0.0% | +23.5% |